Given that we're insterested in a stock deal, or stock heavy deal too, we can bet we're not dealing with big pharma, but a player more ac immunes size, which is solid but with $110 m cash they wouldn't want to afford what we really want. I also think them being European increases the odds. Europeans care more about the diseases elto serves.